Literature DB >> 22402945

Murine models of diabetic nephropathy.

V Peters1, C P Schmitt.   

Abstract

Diabetic nephropathy is the leading cause of end stage renal diseases worldwide. Even though several diabetic animal models exist, not a single one develops renal changes sufficiently reflecting those seen in humans. This review provides an overview on mouse models presenting with various features of diabetic nephropathy. The critical analysis and comparison of existing mouse models substantially enhances our understanding of the disease process and should provide a guide for choosing the most suitable mouse model for the investigation of diabetic nephropathy. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2012        PMID: 22402945     DOI: 10.1055/s-0032-1304569

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  4 in total

Review 1.  Anti-fibrosis therapy and diabetic nephropathy.

Authors:  Anil Karihaloo
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

2.  Longitudinal Changes in Measured Glomerular Filtration Rate, Renal Fibrosis and Biomarkers in a Rat Model of Type 2 Diabetic Nephropathy.

Authors:  Zhi Su; Deborah Widomski; Ji Ma; Marian Namovic; Arthur Nikkel; Laura Leys; Lauren Olson; Katherine Salte; Diana Donnelly-Roberts; Timothy Esbenshade; Steve McGaraughty
Journal:  Am J Nephrol       Date:  2016-10-14       Impact factor: 3.754

3.  Identification of an astrovirus commonly infecting laboratory mice in the US and Japan.

Authors:  Terry Fei Fan Ng; Nikola O Kondov; Nobuhito Hayashimoto; Ritsuki Uchida; Yunhee Cha; Ashley I Beyer; Walt Wong; Patricia A Pesavento; Hiroshi Suemizu; Marcus O Muench; Eric Delwart
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

4.  Suramin: a potential therapy for diabetic nephropathy.

Authors:  Midhun C Korrapati; Lauren A Howell; Lauren H Howell; Brooke E Shaner; Judit K Megyesi; Leah J Siskind; Rick G Schnellmann
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.